By Sabela Ojea

GlaxoSmithKline PLC said Monday that interim analysis of the HIV Prevention Trials Network 083 study has proved the efficacy and safety of investigational, long-acting, injectable cabotegravir inhibitor for HIV prevention.

The British pharmaceutical giant said that the study of cabotegravir was 69% more effective in preventing HIV acquisition when administered every two months in men who have sex with men and transgender women who have sex with men "when compared to the current standard of care, daily oral emtricitabine/tenofovir" drugs.

The London-listed company added that the study had around 4,600 participants across America, Asia and Africa.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

May 18, 2020 02:44 ET (06:44 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Gsk.
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Gsk.